Recent 8-K filings for KALA
Highest-materiality recent filing
KALA BIO faces asset foreclosure by Oxford; CEO terminated, all staff reduced, expects delisting
- Oxford Finance forecloses on all assets, swept substantially all cash; still owed ~$9.6M.
- Board terminated all employees not needed for foreclosure; CEO Todd Bazemore terminated without cause but stays as director/PEO.
-
KALA BIO launches AI infrastructure platform; licenses Researgency from Younet AI
Exclusive worldwide license to Researgency platform for biotech field; initial 12-month term with renewal options.
-
KALA BIO CEO & CFO David Lazar resigns; director Avi Minkowitz appointed same day
David Lazar resigned as CEO and CFO effective Feb 2, 2026, remains on board.
-
KALA BIO sells $4.2M Series AAA Preferred, board control shifts to AK Holdings
Company issued 2.1M shares of Series AAA Preferred at $2/sh, raising $4.2M; each share convertible into 420 common shares (882M total potential shares).
-
KALA BIO receives Nasdaq bid price deficiency notice; 180-day compliance period until July 20, 2026
Letter dated Jan 20, 2026; closing bid price below $1.00 for 30 consecutive business days (Dec 3, 2025–Jan 16, 2026).
-
KALA BIO enters $15M at-market offering agreement with H.C. Wainwright
Aggregate market value of shares eligible for sale under ATM prospectus supplement currently $15,000,000.
-
KALA BIO settles $10.6M Oxford debt for $2M; issues 4.6M shares to settle claims
Paid $2M to Oxford Finance, settling ~$10.6M debt obligations in full; debt overhang removed.
-
Kala Bio pays $2M to settle $10.6M Oxford debt; loan obligations fully satisfied
Paid Oxford Finance $2 million on Dec 26, 2025 under prior Settlement Agreement.
-
KALA Bio dismisses Deloitte, appoints HTL as auditor; 6 directors offer conditional resignations
Audit committee approved HTL International as independent auditor for FY 2025, replacing Deloitte & Touche.
-
KALA BIO CEO Lazar sells Series AAA preferred rights; consultant hired for strategic alternatives
Annual meeting set for Jan 30, 2026; stockholder proposals and director nominations due Dec 27, 2025.
-
KALA BIO raises $10M in registered direct offering of common stock and pre-funded warrants
Sold 900K shares and pre-funded warrants for 9.1M shares at $1.00 per share (warrants at $0.9999).
-
KALA BIO enters $6M private placement, resolves Oxford default, appoints David Lazar as CEO
First closing raised $1.8M from 900k Series AA preferred shares at $2/share; second closing up to $4.2M subject to stockholder approval.
-
KALA BIO receives Nasdaq deficiency notice for MVLS below $35M; 180 days to comply
Nasdaq notified KALA BIO on Nov 10, 2025 that MVLS was below $35M for 30 consecutive business days, violating Listing Rule 5550(b)(2).
-
KALA Bio enters $375k convertible loan; Oxford pauses foreclosure, company faces cash crunch
Convertible loan of up to $375k from individual investor; first $187.5k due Nov 10, remainder by Nov 12, 2025.
-
KALA BIO faces asset foreclosure by Oxford; CEO terminated, all staff reduced, expects delisting
Oxford Finance forecloses on all assets, swept substantially all cash; still owed ~$9.6M.
-
KALA halts pipeline, cuts 51% of staff, grants retention bonuses to top executives
Ceased development of KPI-012 and stem cell platform; workforce reduced by ~19 employees (~51%).
-
KALA BIO receives default notice from Oxford; $29.1M debt accelerated
Oxford Finance declared event of default under Loan Agreement citing Material Adverse Change.
-
KALA BIO Phase 2b trial fails; KPI-012 development halted; workforce cut 51%
CHASE Phase 2b trial of KPI-012 for PCED did not meet primary endpoint of complete healing at Week 8; secondary endpoints also failed.
-
KALA BIO appoints Todd Bazemore as permanent CEO; board election, updated compensation
Todd Bazemore appointed CEO effective Aug 29, 2025, replacing his interim CEO role; also elected Class II director.
-
KALA BIO completes enrollment in Phase 2b trial of KPI-012 for PCED; topline data expected Q3 2025
CHASE trial randomized 79 patients across 37 sites in US and Latin America.
-
KALA BIO Q1 net loss $8.9M; cash $42.2M; KPI-012 Phase 2b topline data due Q3 2025
Cash and cash equivalents of $42.2M as of March 31, 2025, expected to fund operations into Q1 2026.
-
KALA BIO posts Q4 net loss of $8.2M; Phase 2b topline data delayed to 3Q25
Randomized 87 patients in Phase 2b CHASE trial for KPI-012; extending enrollment due to 13 unverified patients; topline data now expected in 3Q25.
Earnings & guidance
Materiality & sentiment trend
Max materiality 1.00 · Median 0.65 · Most common event other_material